Table 1.

Relationship between baseline fibrosis scores and mortality among NHANESIII participants with NAFLD

	NAFLD-FS	APRI	FIB-4
All-cause mortality	Hazard Ratio (95% CI)*	Hazard Ratio (95% CI)*	Hazard Ratio (95% CI)*
- Low score	Reference	Reference	Reference
- Medium score	1.26 (0.98–1.64)	1.32 (0.78–2.23)	1.46 (1.16–1.83)
- High score	1.69 (1.09–2.63)	1.85 (1.02–3.37)	1.66 (0.98–2.82)
Cardiovascular mortality
- Low score	Reference	Reference	Reference
- Medium score	2.16 (1.41–3.29)	0.97 (0.40–2.34)	1.75 (1.26–2.43)
- High score	3.46 (1.91–6.25)	2.53 (1.33–4.83)	2.68 (1.44–4.99)
Liver disease mortality
- Low score	Reference	Reference	Reference
- Medium score	0.49 (0.08–2.83)	6.08 (0.77–48.21)	0.68 (0.11–4.05)
- High score	0.07 (0.00–1.25)	3.01 (0.20–45.62)	1.32 (0.12–14.80)

^*Hazard ratio adjusted for age, gender, race/ethnicity, education, income, diabetes, hypertension, history of cardiovascular disease, lipid lowering therapy, smoking, waist circumference, alcohol consumption, caffeine intake, total cholesterol, HDL-cholesterol, transferrin saturation, and C-reactive protein.

NHANESIII – National Health and Nutritional Examination Survey III; NAFLD – Nonalcoholic Fatty Liver Disease; NAFLD-FS: NAFLD Fibrosis Score; APRI: AST to Platelet Ratio Index; FIB-4: Fibrosis 4 Score